---
---

# 21 U.S.C., USLM ref /us/usc/t21/s399a

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../..//us/usc/t21/ch9/schX/m__us_usc_t21_s399.md) | [Next](./../../../../..//us/usc/t21/ch9/schX/m__us_usc_t21_s399b.md) | [Root of Title](./../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs399a)

## § 399a. Office of the Chief Scientist

    (a) __Establishment; appointment__ 

        The Secretary shall establish within the Office of the Commissioner an office to be known as the Office of the Chief Scientist. The Secretary shall appoint a Chief Scientist to lead such Office.

    (b) __Duties of the Office__ 

    The Office of the Chief Scientist shall—

        (1) oversee, coordinate, and ensure quality and regulatory focus of the intramural research programs of the Food and Drug Administration;

        (2) track and, to the extent necessary, coordinate intramural research awards made by each center of the Administration or science-based office within the Office of the Commissioner, and ensure that there is no duplication of research efforts supported by the Reagan-Udall Foundation for the Food and Drug Administration;

        (3) develop and advocate for a budget to support intramural research;

        (4) develop a peer review process by which intramural research can be evaluated;

        (5)

         identify and solicit intramural research proposals from across the Food and Drug Administration through an advisory board composed of employees of the Administration that shall include—

            (A) representatives of each of the centers and the science-based offices within the Office of the Commissioner; and

            (B) experts on trial design, epidemiology, demographics, pharmacovigilance, basic science, and public health; and

        (6) develop postmarket safety performance measures that are as measurable and rigorous as the ones already developed for premarket review.

([June 25, 1938, ch. 675][/us/act/1938-06-25/ch675], § 1010, formerly § 910, as added [Pub. L. 110–85, title VI][/us/pl/110/85/tVI], § 602, Sept. 27, 2007, [121 Stat. 898][/us/stat/121/898]; renumbered § 1010, [Pub. L. 111–31, div. A, title I][/us/pl/111/31/dA/tI], § 101(b)(2), June 22, 2009, [123 Stat. 1784][/us/stat/123/1784].)

----------

[Previous](./../../../../..//us/usc/t21/ch9/schX/m__us_usc_t21_s399.md) | [Next](./../../../../..//us/usc/t21/ch9/schX/m__us_usc_t21_s399b.md) | [Root of Title](./../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs399a)

----------
----------

[/us/act/1938-06-25/ch675]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1938-06-25%2Fch675
[/us/pl/110/85/tVI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F110%2F85%2FtVI
[/us/stat/121/898]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F121%2F898
[/us/pl/111/31/dA/tI]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F111%2F31%2FdA%2FtI
[/us/stat/123/1784]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F123%2F1784


